University of Thessaly (UTH)
Ανοσοϊστοχημική μελέτη φαινοτυπικών αλλοιώσεων μεσολόβιων πόρων στην πρωτοπαθή χολική κίρρωση
Abstract
dc:descriptionPrimary Biliary Cirrhosis (PBC) is a chronic cholestatic liver disease of unknown aetiology and autoimmune origin, characterized by progressive destruction of small intrahepatic bile ducts, affecting mainly middle-aged women. Hallmark for the serological diagnosis of PBC is the detection of anti-mitochondrial antibodies (AMA).3 diagnostic criteria are currently in use for the disease: detection of AMA by immunoflorecence (IFL) techniques, titers ≥ 1:40, elevated cholestatic live enzymes for more than 6 months, with exclusion of other aetiologies and compatible liver biopsy.A special group of the disease is that of patients with early PBC. They are characterized by repetitive AMA positivity (≥ 1:40), but normal liver function tests and absence of symptoms. According to the literature, they do have PBC, but their disease has slow progression and rare evolution to portal hypertension or cirrhosis.Another category of autoantibodies in PBC is the PBC specific anti- nuclear antibodies (ANA). They exhibit remarkable specificity and their detection is of explicit value in the identification of AMA negative PBC patients ( 5% of PBC patients). The antibody against Promyelocytic Leukaemia protein, (anti- PML antibody) belongs to this category. Detected at first place in patients with Acute Promyelocytic Leukemia, it has also been found in chronic graft-versus-host disease (GVHD). Serum of patients with PBC is positive for anti- PML antibodies in a percentage between 8,7% - 41,2%, depending on the method applied for their detection, and they are thought to be a prognostic marker of severe disease and bad outcome. They develop Multiple Nuclear Dots (MND) pattern, by IFL on human epithelial (HEp-2) cells. Those antibodies co-exist and correlate with the antibodies against sp- 100 protein (anti- sp100 antibodies). There is only one more report of anti- PML detection in human liver biopsies. The purpose of our study was:a) To define the frequency of anti- PML antibodies in liver biopsies of PBC patients and compare it with patients with other liver diseases.b) To find the correlation of anti- PML antibodies with clinical and laboratory characteristics and with the presence of other autoantibodies in the serum of PBC patients.c) To investigate the possibility that anti- PML antibodies detection may contribute to the diagnosis of early PBC.d) To find a possible association between anti- PML presence and PBC prognosis or favorable response to therapy with ursodeoxycholic acid (UDCA).e) To identify their diagnostic significance and their ability to discriminate PBC from other liver diseases.Our study found that anti- PML antibodies are detected in a significantly higher proportion of PBC patients (59,5%) against patients with other liver diseases [13,8% in Primary Sclerosing Cholangitis (PSC) patients, 25% in patients with chronic Hepatitis Β virus (HBV) infection, 33,3% in patients with chronic Hepatitis C virus (HCV) infection, 11,1% in patients with Non Alcoholic Steatohepatitis (NASH), and only 5% in patients with early PBC]. They are detected in a distinctive and unique manner, across the bile ducts of PBC patients, so that differentiation from other liver diseases is accomplished.Their detection in liver tissue in 59,5% of PBC patients was much greater than that achieved in serum (8,7% - 41,2%, according to the study). With application of our immunocytochemistry method we were able to detect patients that no method applied in the serum could detect. Specificity, positive and negative predictive value of our method (79,7%, 62,5% and 77,6% respectively) were sufficient for the discrimination of PBC amongst patients with other liver diseases. A direct correlation between anti- PML staining and histologic progression of the disease was found. Furthermore, correlation with symptomatic, more severe disease and with disease duration was observed, as well as with biochemical markers of disease severity such as serum bilirubin, albumin, immunoglobulins and alkaline phosphatase. No corellation was found with prognostic markers or models, or scores for the prediction of response to UDCA.Positive correlation with MND pattern by IFL on HEp-2 cells, with AMA and anti-soluble liver antigen/ liver-pancreas antibodies (anti-SLA/LP) detection in serum was also found while negative correlation with anti-smooth muscle antibodies (aSMA) and parietal cell antibodies (PCA) / gastric parietal cells (GPA) antibodies detection was observed.Anti- PML antibodies are not sufficiently detected in early PBC patients, and should not be used for this PBC group.Adoption of PML score made the quantification of our method possible, so that more accurate study could be performed.New studies should be performed, to further clarify the significance of anti- PML antibodies, with possible diagnostic or therapeutic prospects for PBC in the future.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papamichalis, Panagiotis
- Παπαμιχάλης, Παναγιώτης
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/34730